[{"orgOrder":0,"company":"OS Therapies","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2025","type":"Acquisition","leadProduct":"Axalimogene Filolisbac","moa":"E7","graph1":"Oncology","graph2":"Phase III","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ OS Therapies","highestDevelopmentStatusID":"10","companyTruncated":"OS Therapies \/ OS Therapies"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OST31-154","moa":"HER-2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Brookline Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Brookline Capital Markets"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Private Placement","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Brookline Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Brookline Capital Markets"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Brookline Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Brookline Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Brookline Capital Markets"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Children's Oncology Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Children's Oncology Group","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Children's Oncology Group"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"OST31-154","moa":"HER-2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"ADXS-503","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ OS Therapies","highestDevelopmentStatusID":"7","companyTruncated":"OS Therapies \/ OS Therapies"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Noble Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series A Financing","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Noble Capital Markets","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Noble Capital Markets"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ADXS31-164","moa":"ErbB2","graph1":"Oncology","graph2":"Phase II","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"OST31-154","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OS Therapies \/ Inapplicable"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapies \/ OS Therapies"},{"orgOrder":0,"company":"OS Therapies","sponsor":"Ayala Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Attenuted Listeria Monocytogene","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"OS Therapies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OS Therapies \/ OS Therapies","highestDevelopmentStatusID":"5","companyTruncated":"OS Therapies \/ OS Therapies"}]
Find Clinical Drug Pipeline Developments & Deals by OS Therapies
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
